PA21 Phase II Clinical Study in Hemodialysis Patients With Hyperphosphatemia

To investigate dose-response efficacy and safety in hemodialysis patients with hyperphosphatemia.

Inclusion Criteria:

• Patients age 20 or older, regardless of gender.
• Receiving stable maintenance hemodialysis 3 times a week.
• Patients not having changed their phosphate binder agent dose, for 4 weeks or more before their observation period start.

Exclusion Criteria:

• Patients having history of a pronounced brain / cardiovascular disorder.
• Patients having severe gastrointestinal disorders.
• Patients having severe hepatic disorders.